Central European Journal of Medicine

, Volume 7, Issue 5, pp 659–664 | Cite as

Asymmetric and symmetric dimethylarginine in patients presenting with risk factors for coronary heart disease

  • Marina Deljanin Ilic
  • Radmila Pavlovic
  • Gordana Lazarevic
  • Tatjana Cvetkovic
  • Gordana Kocic
  • Stevan Ilic
  • Vladisav Stefanovic
Research Article


The aim of the present study was to investigate asymmetric (ADMA) and symmetric dimethylarginine (SDMA) production in patients presenting with one or more risk factor (RF) for coronary heart disease (CHD). Patients and methods: Overall, 113 participants were enrolled in the study, including 45 patients presenting with risk for CHD (27 male and 18 female; aged 55.9 ± 6.4 years), 30 sex and age-matched middle-aged healthy controls (16 male and 14 female; aged 56.3 ± 8.4 years), and 38 young healthy controls (38 male; aged 24.6 ± 3.9 years). Results: No significant differences for ADMA and SDMA were recorded between patients groups presenting with risk for CHD. However, ADMA and SDMA were significantly higher in all examined patient groups (≥3 and 1–2 RF, hypertensive and non-hypertensive, obese and non-obese, diabetics and non-diabetics) compared with both control groups (middle-aged and young controls) (p<0.001). ADMA significantly correlated with SDMA in ≥3 RF (p<0.05), hypertensive (p<0.05), non-obese (p<0.05), non-diabetics (p<0.01), as well in middle-aged (p<0.05) and young controls (p<0.001). Conclusion: Significantly higher ADMA and SDMA were found between patients presenting with risk for CHD (≥3 and 1–2 RF, hypertensive and nonhypertensive, obese and non-obese, diabetics and non-diabetics) and healthy, middle-aged and young controls. ADMA significantly correlated with SDMA in ≥3 RF, hypertensive, non-obese and non-diabetic patients, as well as in middle-aged and young controls.


Nitric oxide Asymmetric and symmetric dimethylarginine Coronary heart disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109(II): 27–33Google Scholar
  2. [2]
    Valkonen V, Päivä H, Salonen J, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–2128PubMedCrossRefGoogle Scholar
  3. [3]
    Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012PubMedCrossRefGoogle Scholar
  4. [4]
    Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119:1592–1600PubMedCrossRefGoogle Scholar
  5. [5]
    Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30:1142–1150PubMedCrossRefGoogle Scholar
  6. [6]
    Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with Type 2 diabetes. Diabetes Care 2007; 30: 1834–1839PubMedCrossRefGoogle Scholar
  7. [7]
    Meinitzer, Seelhorst U, Wellnitz B, Schernthaner G. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53:273–283PubMedCrossRefGoogle Scholar
  8. [8]
    Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383–388PubMedCrossRefGoogle Scholar
  9. [9]
    Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53:1574–1579PubMedCrossRefGoogle Scholar
  10. [10]
    Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011; 57:112–121PubMedCrossRefGoogle Scholar
  11. [11]
    Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via storeoperated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24:1429–1435PubMedCrossRefGoogle Scholar
  12. [12]
    Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G, Holt DW, Willeit J, Xu Q, Mayr M. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009; 205:261–265PubMedCrossRefGoogle Scholar
  13. [13]
    Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function — a meta-analysis. Nephrol Dial Transplant 2006; 21:2446–2451PubMedCrossRefGoogle Scholar
  14. [14]
    Paroni R, Fermo I, Fiorina P, Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 2005; 28: 389–94PubMedCrossRefGoogle Scholar
  15. [15]
    Deljanin Ilic M, Ilic S, Lazarevic G, Kocic G, Pavlovic R, Stefanovic V. Impact of reversible myocardial ischaemia on nitric oxide and asymmetric dimethylarginine in patients with high risk for coronary artery disease. Med Sci Monit 2010; 16:CR394–404Google Scholar
  16. [16]
    Böger R, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60:481–487PubMedCrossRefGoogle Scholar
  17. [17]
    Cable DG, Celotto AC, Barbosa Evora PR, Schaff HV. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit 2009; 15:248–253Google Scholar
  18. [18]
    Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006; 49:351–359PubMedCrossRefGoogle Scholar
  19. [19]
    Cetinalp-Demircan P, Can A, Bekpinar S, Unlucerci Y, Orhan Y. Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease. Endocrine 2007; 31:100–104PubMedCrossRefGoogle Scholar
  20. [20]
    Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 201–1203CrossRefGoogle Scholar
  21. [21]
    Candido R, Zanetti M. Endothelial dysfunction in diabetic vascular disease, Ital Heart J 2005; 6: 703–720PubMedGoogle Scholar
  22. [22]
    Lenzen H, Tsikas D, Böger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006; 62: 45–49CrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Marina Deljanin Ilic
    • 1
  • Radmila Pavlovic
    • 2
  • Gordana Lazarevic
    • 3
  • Tatjana Cvetkovic
    • 4
  • Gordana Kocic
    • 4
  • Stevan Ilic
    • 1
  • Vladisav Stefanovic
    • 5
  1. 1.Institute of Cardiology, Niska Banja, Faculty of MedicineUniversity of NisNisSerbia
  2. 2.Institute of Chemistry, Faculty of MedicineUniversity of NisNisSerbia
  3. 3.Clinic of CardiologyClinical Center, NisNisSerbia
  4. 4.Institute of Biochemistry, Faculty of MedicineUniversity of NisNisSerbia
  5. 5.Institute of Nephrology, Faculty of MedicineUniversity of NisNisSerbia

Personalised recommendations